Cardiff Oncology is a biotech company. The company develops therapies and treatments for solid tumor and hematologic cancers. It provides onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Cardiff Oncology's clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.